ALTRUBIO
AltruBio is focused on developing targeted antibody therapeutics for the treatment of cancer and immune-related inflammatory diseases. AltruBio International in Delaware with principal office in SFO Bay Area California is a biopharmaceutical company integrated globally and virtually to develop targeted antibody therapeutics for the treatment of cancer and immune-related inflammatory diseases. With its R&D foundation in Taipei Taiwan since June 2000, AbGenomics has been focusing on the discover... y and development of novel therapeutics for unmet medical needs. Their R&D scientists built an efficient discovery platform to identify and validate novel antibody therapeutics. Currently, AbGenomics has several potential therapeutic antibodies targeting autoimmune diseases, pancreatic cancer, stomach cancer, colorectal cancer, ovarian cancer, lung cancer, and other solid tumors in various development stages.
ALTRUBIO
Social Links:
Industry:
Biotechnology Health Care Medical
Founded:
2000-06-01
Address:
Los Altos, California, United States
Country:
United States
Website Url:
http://www.altrubio.com
Total Employee:
11+
Status:
Active
Contact:
(650) 988-9912
Email Addresses:
[email protected]
Total Funding:
327.61 M USD
Technology used in webpage:
Mobile Non Scaleable Content U.S. Server Location CrUX Dataset CrUX Top 10m Amazon Frankfurt Region Laravel
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focusesย on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
CEL-SCI
CEL-SCI is a biotechnology company developing immunotherapy products for the treatment of cancer and other infectious diseases.
Edison Pharmaceuticals
Edison Pharmaceuticals develops medicines for the treatments of children and adults diagnosed with rare and neglected diseases.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Synta Pharmaceuticals
Synta Pharmaceuticals is focused on developing and commercializing small molecule drugs to treat cancer and chronic inflammatory diseases.
Vital Therapies
Vital Therapies is a biotech company focused on developing a cell-based therapy targeting the treatment of acute liver failure.
Current Advisors List
Current Employees Featured
Founder
Investors List
Soleus Capital
Soleus Capital investment in Series B - AltruBio
RA Capital Management
RA Capital Management investment in Series B - AltruBio
Blackstone Group
Blackstone Group investment in Series B - AltruBio
aMoon Fund
aMoon Fund investment in Series B - AltruBio
Cormorant Asset Management
Cormorant Asset Management investment in Series B - AltruBio
Delos Capital
Delos Capital investment in Series B - AltruBio
Biotechnology Value Fund
Biotechnology Value Fund investment in Series B - AltruBio
CAM Capital
CAM Capital investment in Series A - AltruBio
aMoon Fund
aMoon Fund investment in Series A - AltruBio
Biotechnology Value Fund
Biotechnology Value Fund investment in Series A - AltruBio
Key Employee Changes
Date | New article |
---|---|
2021-09-13 | AltruBio snags a CMO after pivot from oncology to immunology |
2021-08-09 | AltruBio Strengthens Management Team With Appointment of Jeroen Grasman as Chief Financial Officer |
Official Site Inspections
http://www.altrubio.com Semrush global rank: 5.08 M Semrush visits lastest month: 1.58 K
Unable to get host informations!!!
More informations about "AltruBio"
AltruBio
Before taking on her current roles, she headed the global Biotech organization at Bayer Pharmaceuticals overseeing the development, manufacturing and distribution of Bayerโs โฆSee details»
AltruBio Inc. - LinkedIn
Dr. Judy Chou, PhD, is the President, CEO, and member of the Board of Directors of AltruBio Inc., Inc., a clinical-stage biotech company focused on developing novel therapeutics for the โฆSee details»
Org Chart AltruBio - The Official Board
The organizational chart of AltruBio displays its 14 main executives including Judy Chou, Jeroen Grasman and Gene LeeSee details»
AltruBio Company Profile | Management and Employees List
AltruBio is a global biopharmaceutical organization that focuses on the development of targeted antibody therapeutics for the treatment of cancer and immune related inflammatory disease. โฆSee details»
AltruBio - Directors Team - The Org
The Directors Team at AltruBio is responsible for guiding the strategic direction of the company, overseeing major business initiatives, and ensuring the successful development and โฆSee details»
AltruBio Company Profile 2024: Valuation, Funding & Investors
Information on valuation, funding, cap tables, investors, and executives for AltruBio. Use the PitchBook Platform to explore the full profile.See details»
AltruBio
More. 2024 . 01 . 12 . Investor's Business DailyโWhy Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space. 2023 .See details»
Altrubio Inc. Company Profile | San Francisco, CA | Competitors ...
Find company research, competitor information, contact details & financial data for Altrubio Inc. of San Francisco, CA. Get the latest business insights from Dun & Bradstreet.See details»
AltruBio - Products, Competitors, Financials, Employees, โฆ
AltruBio Announces Formation of Scientific Advisory Board. Dec 3, 2024. World-renowned researchers with extensive experience in immunology and autoimmune diseases join AltruBio โฆSee details»
AltruBio President and CEO Judy Chou Appointed to the โฆ
SAN FRANCISCO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- AltruBio Inc. (โAltruBioโ or โthe Companyโ), a clinical stage biotech company dedicated to the development of novel โฆSee details»
AltruBio Inc. - BioCentury Company Profiles - BCIQ
May 23, 2024 AltruBio Inc. - BioCentury Company Profiles for the biopharma industrySee details»
AltruBio, Inc. - VentureRadar
"AltruBio is developing first-in-class immune-modulators to target diseases of the immune system. Its world-class global team brings a breadth of expertise in immunology and drug development โฆSee details»
New name, new board, new focus: AltruBio relaunches with $63M โฆ
Apr 15, 2021 AltruBio CEO Judy Chou, Ph.D. (AltruBio) AltruBio would like to reintroduce itself. After shifting from oncology to immunology, swapping out the board and completing a name โฆSee details»
AltruBio President and CEO Judy Chou Appointed to the
Nov 1, 2022 CIRM is a State-funded organization that provides grant awards for research with a goal of accelerating world class science to deliver transformative regenerative medicine โฆSee details»
AltruBio - Company Profile - Tracxn
Dec 6, 2024 AltruBio - Developer of drugs for immune-mediated inflammation and cancer therapies. Raised a total funding of $288M over 2 rounds from 8 investors. Founded by Ron โฆSee details»
AltruBio lands up to $225M after shift to immune drug research
May 21, 2024 Dive Brief: Biotechnology startup AltruBio on Tuesday raised a Series B round that could hand it up to $225 million, cashing in again on a decision four years ago to change its โฆSee details»
AltruBio snags a CMO after pivot from oncology to immunology
Sep 13, 2021 Previously known as AbGenomics Holding, AltruBio changed its focus from oncology to immunology in April this year. The company is developing antibody treatments for โฆSee details»
Immune checkpoint enhancer biotech AltruBio raises $225m
May 22, 2024 A healthy run of nine-figure private rounds for biotechs in the US has continued with an impressive $225 million Series B for immunotherapy specialist AltruBio.See details»
AltruBio raises $225M for midphase ulcerative colitis program
May 21, 2024 AltruBio put ALTB-268 through a phase 1 study in healthy volunteers in 2023, leading to the initiation of a midphase study in patients with ulcerative colitis who are refractory โฆSee details»
Ale Rubio - FIT by You
Únete a una comunidad que integra entrenamiento, nutrición y wellness. Con un enfoque preciso y confiable que se ajusta a tus necesidades, horarios y siempre impulsándote hacia adelante โฆSee details»